Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bio Path Holdings Inc BPTH

Healthcare Biotechnology
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction... see more

NDAQ:BPTH - Post Discussion

Bio Path Holdings Inc > Bio-Path Holdings Reports Positive Phase 1/1b BP1002 Clinica
View:
Post by whytestocks on Apr 18, 2024 10:15am

Bio-Path Holdings Reports Positive Phase 1/1b BP1002 Clinica

NEWS: $BPTH Bio-Path Holdings Reports Positive Phase 1/1b BP1002 Clinical Trial Data2024-04-18 07:44:14 ET DENVER, Colo., Apr 18, 2024 ( 247marketnews.com )- Bio-Path Holdings, Inc., (NASDAQ: BPTH ) reported completing the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractor...BPTH - Bio-Path Holdings Reports Positive Phase 1/1b BP1002 Clinical Trial Data
Be the first to comment on this post
Bio Path Holdings Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities